# Bleximenib

Source: https://onco.cc/drugs/bleximenib/  
OnCo record `bleximenib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bleximenib is an experimental small-molecule drug from Janssen Research & Development in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.

## Summary

Bleximenib (JNJ-75276617) is a small-molecule drug developed by Janssen Research & Development. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06852222 (A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukaemia (AML)), in acute myeloid leukaemia. The largest, NCT06852222, plans to enrol 600 participants with primary completion expected 2029-06-22. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: JNJ-75276617
- Modality: small molecule
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of Bleximenib: https://clinicaltrials.gov/search?intr=JNJ-75276617

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia](https://onco.cc/cancers/aml-npm1-kmt2a/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- trials: [A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)](https://onco.cc/trials/nct06852222/)

---
JSON: https://onco.cc/api/v1/entities/bleximenib.json